One of the most common cancers among men is prostate cancer. It is estimated that about 1 of every 9 men in the United States will be diagnosed with prostate cancer in their lifetime. The older a man gets, the greater the chance of developing prostate cancer. About 60% of prostate cancer cases are diagnosed in men 65 and older, with the average age at the time of being diagnosed is 65.
Next to lung cancer, prostate cancer is the second leading cancer death for men in America. It is estimated that about 1 in 41 men ill die from prostate cancer, but it is also one of the more curable cancers with millions of men surviving prostate cancer, but that depends upon when it is diagnosed, the severity and whether or not the man undergoes treatment. For men receiving treatment, the survival rate is about 90% after 5-years from the time of diagnosis.
My dad was diagnosed with prostate cancer in his late 70’s and died at 92 from totally unrelated causes. I’ve known a number of other men who have been diagnosed with prostate cancer who have lived long and productive lives, but they all were detected early and underwent treatment.
If the prostate cancer is confined to the prostate gland, it can often be totally eliminated with surgery, which can range from removing just the tumor to removing the entire prostate gland.
Other treatments include radiation and chemotherapy, with each having a number of variations. One of the newer forms of radiation treatment for prostate cancer is referred to as prostate-specific membrane antigen (PSMA) treatment.
According to a recent report:
“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.”
“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”
“‘This is a study of cancer that has spread quite widely and is no longer sensitive to standard hormone treatment,’ Michael S. Hofman, MD, professor of nuclear medicine at Peter McCallum Cancer Center in Melbourne, Australia, said during a press cast. ‘There have been major advances in the past few years with several drugs that prolong survival, but the disease remains fatal in a relatively short period of time, and there is an urgent need for more effective treatments’.”
“Lutetium-177 (177Lu)-PSMA-617 (Endocyte) is a radiolabeled small molecule that selectively binds to prostate-specific membrane antigen (PSMA) — a common receptor on prostate cancer cells — allowing beta-radiation to be delivered directly to tumors.”
“Researchers previously reported positive responses to 177Lu-PSMA-617 with low toxicity among 30 men with metastatic, castration-resistant prostate cancer. The updated results include an expansion cohort of 20 men, with median follow-up of 23.5 months.”
So, fellow male seniors, although there is a 1 in 9 chance you could develop prostate cancer, recent breakthroughs in treatment says your prognosis and survivability rate is increasing every day.